RxDoctor Payments Data

Phillip Haddad, MD

Internal Medicine · Shawnee, OKNPI 1326087818

Payments from drug & device makers

$2,457in general payments, 2019–2025

Across 140 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$509
  • GSK$288
  • Sanofi$284
  • Boehringer Ingelheim$253
  • Baxter Healthcare$195
  • Viatris Specialty LLC$185
  • plus $743 from 13 others

What the payments were for

  • Food & beverage$2,35796%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,457 in reported general payments places this provider in the 80th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$205,406
Medicare patients
1,163
Services billed
2,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate87$1,124,484
Trelegy ElliptaFluticasone/Umeclidin/Vilanter1,294$994,661
Fasenra PenBenralizumab26$143,104
EliquisApixaban166$142,708
FasenraBenralizumab15$98,803
OzempicSemaglutide62$95,587
TrulicityDulaglutide81$94,895
Breo ElliptaFluticasone/Vilanterol182$93,550
TezspireTezepelumab-Ekko22$92,617
MounjaroTirzepatide60$68,582
SymbicortBudesonide/Formoterol Fumarate158$55,079
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr60$53,972
XareltoRivaroxaban63$51,817
Combivent RespimatIpratropium/Albuterol Sulfate90$51,272
Fluticasone-SalmeterolFluticasone Propion/Salmeterol222$40,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Combivent Respimat, Spiriva Respimat, Jardiance$253$1,206,294224 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$288$1,160,4401,568 claims
AstraZenecaFasenra, Tezspire, Symbicort, Farxiga, Breztri Aerosphere$178$299,627253 claims
PfizerEliquis$15$142,708166 claims
Sanofi-aventis U.S. LLCMultaq$100$14,23514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Shawnee

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →